PTI Jul 12, 2019, 05.47 PM IST

New Delhi: Drug firm Laurus LabsNSE 3.29 % Friday said audit of its unit 4 at Visakhapatnam in Andhra Pradesh by the US health regulator has been completed without any observations. 

"The inspection of the unit 4 was carried out from July 8 - 12, 2019," Laurus Labs said in a filing to BSENSE -0.83 %. 

The maiden United States Food and Drug Administration (USFDA) audit for the unit was successfully completed without any observations and no Form 483 was issued, it added. 

As per the USFDA, Form 483 notifies the company's management of objectionable conditions.